BOSTON--(BUSINESS WIRE)--Nov. 8, 2017--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to improve the survival and quality of life of cancer patients,
today announced that the Company will present at the following upcoming
The Stifel Nicolaus 2017 Healthcare Conference on Tuesday, November
14, at 10:15 a.m. ET in New York City, NY, USA
The Jefferies 2017 London Healthcare Conference on Thursday, November
16, at 5:20 p.m. GMT in London, UK
A live webcast of each presentation will be available on the investors
section of the Company's website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
PI3K-delta and PI3K-gamma, which has successfully met its primary
endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and
a Phase 3 clinical trial in patients with chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL). In addition, Verastem is
developing the FAK inhibitor defactinib, which is currently being
evaluated in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small cell lung
cancer, and mesothelioma. Verastem’s product candidates seek to treat
cancer by modulating the local tumor microenvironment, enhancing
anti-tumor immunity, and reducing cancer stem cells. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005798/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214